AACR logo

More articles from Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

BRAF^V600E Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis
Chan-Juan Wang, Lei Cui, Hong-Hao Ma, Dong Wang, Li Zhang, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Tian-You Wang, Zhi-Gang Li, Rui Zhang

Molecular Cancer Therapeutics Jul 2021, 20 (7) 1316-1323; DOI: 10.1158/1535-7163.MCT-20-1075
RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Hiroyuki Arai, Shu Cao, Francesca Battaglin, Jingyuan Wang, Natsuko Kawanishi, Ryuma Tokunaga, Fotios Loupakis, Sebastian Stintzing, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M. Mumenthaler, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Joshua Millstein, Heinz-Josef Lenz

Molecular Cancer Therapeutics Jun 2021, 20 (6) 1153-1160; DOI: 10.1158/1535-7163.MCT-20-0649
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Marika K.A. Koivu, Deepankar Chakroborty, Mahlet Z. Tamirat, Mark S. Johnson, Kari J. Kurppa, Klaus Elenius

Molecular Cancer Therapeutics Mar 2021, 20 (3) 564-576; DOI: 10.1158/1535-7163.MCT-20-0590
BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Sara Busacca, Laura O'Regan, Anita Singh, Annabel J. Sharkey, Alan G. Dawson, Joanna Dzialo, Aimee Parsons, Neelam Kumar, Laurel M. Schunselaar, Naomi Guppy, Apostolos Nakas, Michael Sheaff, Aaron S. Mansfield, Sam M. Janes, Paul Baas, Andrew M. Fry, Dean A. Fennell

Molecular Cancer Therapeutics Feb 2021, 20 (2) 379-388; DOI: 10.1158/1535-7163.MCT-20-0363
HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Hiroshi Ureshino, Takero Shindo, Hidenori Tanaka, Hiroh Saji, Shinya Kimura

Molecular Cancer Therapeutics Jan 2021, 20 (1) 142-149; DOI: 10.1158/1535-7163.MCT-20-0336
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
Javier Martín-Broto, Antonio López Pousa, Andrew S. Brohl, Brian A. Van Tine, Benjamin Powers, Silvia Stacchiotti, Jean-Yves Blay, James S. Hu, Gerard J. Oakley, Hong Wang, Anna M. Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, Robin L. Jones

Molecular Cancer Therapeutics Jan 2021, 20 (1) 132-141; DOI: 10.1158/1535-7163.MCT-20-0441
Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations—A Perspective from a Real-World Precision Medicine Cohort
Shai Rosenberg, Ryosuke Okamura, Shumei Kato, Thierry Soussi, Razelle Kurzrock

Molecular Cancer Therapeutics Dec 2020, 19 (12) 2612-2620; DOI: 10.1158/1535-7163.MCT-20-0097
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Yingmiao Liu, Jing Lyu, Kirsten Bell Burdett, Alexander B. Sibley, Ace J. Hatch, Mark D. Starr, John C. Brady, Kelli Hammond, Federica Marmorino, Daniele Rossini, Richard M. Goldberg, Alfredo Falcone, Chiara Cremolini, Kouros Owzar, Anastasia Ivanova, Dominic T. Moore, Michael S. Lee, Hanna K. Sanoff, Federico Innocenti, Andrew B. Nixon

Molecular Cancer Therapeutics Oct 2020, 19 (10) 2146-2154; DOI: 10.1158/1535-7163.MCT-20-0249
Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors
E. Gabriela Chiorean, Susan M. Perkins, R. Matthew Strother, Anne Younger, Jennifer M. Funke, Safi G. Shahda, Noah M. Hahn, Kumar Sandrasegaran, David R. Jones, Todd C. Skaar, Bryan P. Schneider, Christopher J. Sweeney, Daniela E. Matei

Molecular Cancer Therapeutics Oct 2020, 19 (10) 2155-2162; DOI: 10.1158/1535-7163.MCT-20-0277
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabrizio, Andrew B. Sharabi, Shumei Kato, Razelle Kurzrock

Molecular Cancer Therapeutics Oct 2020, 19 (10) 2139-2145; DOI: 10.1158/1535-7163.MCT-20-0161

Main menu

User menu

Search

More articles from Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Pages

Articles

Info for

About MCT